The ideal scaffold for cartilage regeneration is expected to provide adequate mechanical strength, controlled degradability, adhesion, and integration with the surrounding native tissue. As it does this, it mimics natural ECMs functions, which allow for nutrient diffusion and promote cell survival and differentiation. Injectable hydrogels based on tyramine (TA)-functionalized hyaluronic acid (HA) and dextran (Dex) are a promising approach for cartilage regeneration. The properties of the hydrogels used in this study were adjusted by varying polymer concentrations and ratios. To investigate the changes in properties and their effects on cellular behavior and cartilage matrix formation, different ratios of HA- and dextran-based hybrid hydrogels at both 5 and 10% w/v were prepared using a designed mold to control generation. The results indicated that the incorporation of chondrocytes in the hydrogels decreased their mechanical properties. However, rheological and compression analysis indicated that 5% w/v hydrogels laden with cells exhibit a significant increase in mechanical properties after 21 days when the constructs are cultured in a chondrogenic differentiation medium. Moreover, compared to the 10% w/v hydrogels, the 5% w/v hybrid hydrogels increased the deposition of the cartilage matrix, especially in constructs with a higher Dex–TA content. These results indicated that 5% w/v hybrid hydrogels with 25% HA–TA and 75% Dex–TA have a high potential as injectable scaffolds for cartilage tissue regeneration.
Previously, 5% w/v hyaluronic acid-tyramine (HA-TA) and dextran-tyramine (Dex-TA) enzymatically cross-linked hybrid hydrogels were demonstrated to provide a mechanically stable environment, maintain cell viability, and promote cartilaginous-specific matrix deposition in vitro. In this study, 5% w/v hybrid hydrogels were combined with human mesenchymal stem cells (hMSCs), bovine chondrocytes (bCHs), or a combination of both in a 4:1 ratio and subcutaneously implanted in the backs of male and female nude rats to assess the performance of cell-laden hydrogels in tissue formation. Subcutaneous implantation of these biomaterials showed signs of integration of the gels within the host tissue. Histological analysis showed residual fibrotic capsules four weeks after implantation. However, enhanced tissue invasion and some giant cell infiltration were observed in the HA-TA/Dex-TA hydrogels laden with either hMSCs or bCHs but not with the co-culture. Moreover, hMSC-bCH co-cultures showed beneficial interaction with the hydrogels, for instance, in enhanced cell proliferation and matrix deposition. In addition, we provide evidence that host gender has an impact on the performance of bCHs encapsulated in HA-TA/Dex-TA hydrogels. This study revealed that hydrogels laden with different types of cells result in distinct host responses. It can be concluded that 5% w/v hydrogels with a higher concentration of Dex-TA (≥50%) laden with bCH-hMSC co-cultures are adequate for injectable applications and in situ cell delivery in cartilage regeneration approaches.
27 February 2026 in Tissue Engineering Part B: Reviews
Premature ovarian insufficiency (POI) is a clinically heterogeneous disorder characterized by ovarian dysfunction occurring before the age of 40, leading to infertility and increased long-term health risks. Current management strategies alleviate symptoms but fail to restore ovarian function or fertility, thereby prompting an urgent demand for regenerative therapies for POI. Mesenchymal stromal cells (MSCs) have emerged as a promising regenerative strategy due to their multifunctional capabilities, including paracrine effects, immunomodulation, and cytoprotection effects. This review systematically synthesizes preclinical and clinical evidence supporting the efficacy of MSCs in mitigating ovarian damage, enhancing folliculogenesis, restoring hormonal balance, and promoting the restoration of fertility in both POI models and patients. In addition, this article examines ongoing challenges, such as cellular heterogeneity, the determination of optimal transplantation strategies, and ensuring long-term safety. It also highlights innovative approaches, including biomaterial-enhanced transplantation, genetic engineering, and exosome-based therapies. The integration of these advanced strategies within personalized medicine frameworks holds significant potential to transform the clinical management of POI.